Study Shows Ambry Genetics’ Program Impact on Rare Disease Diagnosis
Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc., and a leader...